



TFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: UIC0005US.NP

Inventors: Kumar et al.

Serial No.: 10/567,958

Filing Date: Not Yet Assigned

Examiner: Not Yet Assigned

Customer No.: 26259

Group Art Unit: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Title: Silencing of TGF-Beta Receptor Type II
Expression by siRNA

I, Jane Massey Licata, Registration No. 32,257,
certify that this correspondence is being deposited
with the U.S. Postal Service as First Class mail in
an envelope addressed to the Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450

On this date: April 4, 2006

Jane Massey Licata
Jane Massey Licata, Registration No. 32,257

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is attached hereto; or

() Authorization to charge Deposit Account No. 50-1619 the fee of \$180.00 as set forth in §1.17(p) is provided.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.


() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,



Jane Massey Licata
Registration No. 32,257

Date: April 4, 2006

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515



Form PTO 1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce	Docket No. UIC0005US.NP	Serial No. 10/567,958
	Applicant Kumar et al.	
	Filing Date Not Yet Assigned	Group Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AA	Arias et al., "Adenoviral Delivery of an Antisense RNA Complementary to the 3' Coding Sequence of Transforming Growth Factor- β 1 Inhibits Fibrogenic Activities of Hepatic Stellate Cells ¹ ", Cell Growth & Differentiation 2002 13:265-273
	AB	Cordeiro et al., Novel antisense oligonucleotides targeting TFG- β inhibit in vivo scarring and improve surgical outcome", Gene Therapy 2003 10:59-71
	AC	Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", Nature 2001 411:494-498
	AD	Fire et al., "Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> ", Nature 1998 391:806-811
	AE	Hannon, Gregory J., "RNA interference", Nature 2002 418:244-251
	AF	Reich et al., "Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model", Molecular Vision 2003 9:210-216
	AG	Shen et al., "Specific inhibition of transforming growth factor- β 2 expression in human osteoblast cells by antisense phosphorothioate oligonucleotides", Eur. J. Biochem. 2001 268:2331-2337
	AH	Song et al., "RNA interference targeting Fas protects mice from fulminant hepatitis", Nature Medicine 2003 9(3):347-351
	AI	Su et al., "Ribozyme to Human TGF- β 1 mRNA Inhibits the Proliferation of Human Vascular Smooth Muscle Cells", Biochemical and Biophysical Research Communications 2000 278:401-407

EXAMINER	DATE CONSIDERED
-----------------	------------------------

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Docket No. UIC0005US.NP	Serial No. 10/567,958
		Applicant Kumar et al.	
		Filing Date Not Yet Assigned	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AJ	Yamamoto et al., "Ribozyme Oligonucleotides Against Transforming Growth Factor- β Inhibited Neointimal Formation After Vascular Injury in Rat Model", Circulation 2000 102:1308-1314	
	AK	NCBI Genbank Accession M85079 [gi:339569] 31 July 1992 - 14 January 1995 with Revision History	
EXAMINER		DATE CONSIDERED	